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http://dx.doi.org/10Background and Aims. Cardiac valve calcification (VC) is a frequent complication in
chronic kidney disease and is considered a risk factor for all-cause and cardiovascular
mortality. However, little is known about the pathophysiology mechanisms that originate
it and the factors associated with its development. We undertook this study to analyze the
frequency and factors related to de novo development of mitral valve calcification (MVC)
and aortic valve calcifications (AVC) in incident peritoneal dialysis (PD) patients.
Methods. A prospective cohort of 124 incident PD patients was studied. Demographic
and clinical data were recorded and blood assayed at baseline and after 1 year of
follow-up for calcium, phosphorus, glucose, urea, creatinine, cholesterol, triglycerides
by spectrophotometry assay; high-sensitivity C-reactive protein (CRP) by immunoturbi-
dimetric ultrasensitive assay, intact parathormone (iPTH) and osteocalcin by electroche-
miluminescence, fetuin-A and osteoprotegerin by EDI-ELISA. Valve calcification was
evaluated by M-mode bidimensional echocardiogram.
Results. Sixty eight percent of patients were male, ages 43  13 years; 51% were dia-
betic with 1.4  1 months on PD. After 12.3  1 months, 57 patients (46%) developed
VC: AVC in 33 (57.8%), MVC in 15 (26.3%) and 9 (15.8%) patients in both valves.
There was no correlation between AVC and MCV. In univariate logistic regression anal-
ysis, age, diabetes and elevated concentrations of OPG, iPTH and CRP were risk factors
for development MVC. In multivariate analysis, only iPTH remained an independent risk
factor as was also the case in AVC.
Conclusions. Age, diabetes, osteoprotegerin, parathormone and C-reactive protein are
risk factors related to de novo development of MVC and iPTH for AVC in incident dial-
ysis patients.  2013 IMSS. Published by Elsevier Inc.
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Presence of heart valve calcification is associated with
chronic kidney disease (CKD); more advanced stages have
higher rates of valve calcification (1,2). Valve calcification
may be 5 to 10 times more frequent in patients with end-
stage renal disease (ESRD) in comparison with a non-Inc.
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ported for mitral valve calcification (MVC) and 25e52.0%
for aortic valve calcification (AVC) in hemodialysis (HD)
patients (4,5). Similar data were also reported in peritoneal
dialysis (PD) patients (6).
Heart valve calcifications are associated with other
vascular pathological conditions such as atherosclerosis
and vascular calcifications (7) and have also been identified
as risk factors for cardiovascular morbidity and mortality.
MVC was associated with atrial fibrillation, stroke, and
increased morbidity and mortality of cardiovascular origin
in both the general and the CKD populations (8e10). On
the other hand, AVC was reported as a risk factor for car-
diovascular morbidity and mortality (11).
In spite of its high frequency and importance as a risk
factor for cardiovascular mortality in CKD patients, little
is known about the mechanisms and risk factors for their
development. In cross-sectional studies, MVC was associ-
ated with inflammation (12) and hyperphosphatemia (4),
and AVC seems to be associated with duration of HD treat-
ment and some markers of mineral metabolism (13,14).
However, studies about the development of new valve cal-
cifications are not available. The aim of this study was to
analyze the frequency and factors related to de novo devel-
opment of MVC and AVC in incident PD patients.Materials and Methods
Design
A prospective cohort study was performed in ESRD pa-
tients from six dialysis units in the metropolitan area of
Mexico City affiliated with the national network of the
Instituto Mexicano del Seguro Social. The protocol was
approved by the Human Research and Ethics Commit-
tees of each of the participating hospitals. Patients gave
their signed informed consent before enrollment in the
study.
Patient Population
Two hundred forty-eight patients initiated PD in six hospi-
tals participating in the study in the period between October
2009 and August 2010. Of these patients, 133 (54%) met
the inclusion criteria. Of those accepted, three died, one
was lost to follow-up and five had valve calcification at
baseline and were excluded; 124 patients (50%) of the total
population were included in the final analysis.
The patients were considered eligible for inclusion if
they were incident (!3 months) on continuous ambulatory
peritoneal dialysis (CAPD) or automated peritoneal dialysis
(APD). All were adults (18 years or older) without selection
by gender, cause of renal disease or dialysis modality.
Patients were excluded if they had pre-existing heart
valve calcifications, heart failure, infections, malignancy,
chronic liver disease, seropositivity for hepatitis or HIVor if they received immunosuppressive treatment. Patients
with incomplete data were also excluded. All patients were
dialyzed using conventional lactate-buffered glucose-based
PD solutions. The patients received medications such
as antihypertensives, calcium based-phosphate binders
(CaCO3 average 2.5 g/day) and 1a25 (OH)2 D3, (calcitriol,
0.25e0.75 mg/day) as indicated by their attending
physicians.
Data Collection
After enrollment, basal clinical, biochemical and echocar-
diographic evaluations were performed. Second (final)
similar evaluations took place at 12 months of follow-up.
In the meantime, patients were followed by their health care
team with bimonthly visits for their regular treatment and
unscheduled visits and treatment as needed.
Demographic and Clinical Data
Demographic and clinical data were obtained from clinical
files or directly from patient during scheduled visits. They
included age, gender, smoking status, systolic and diastolic
blood pressure (BP), body mass index, diabetes mellitus
status, evolution time of kidney disease, and PD and phar-
macology prescriptions.
Biochemical Parameters
Fasting venous blood samples were drawn for biochemical
analyses. Glucose, urea, creatinine, albumin, cholesterol, tri-
glycerides, total calcium (tCa), and phosphorous (PO4) were
performed by conventional spectrophotometry assay. High-
sensitivity C-reactive protein (hs-CRP) was measured using
the immunoturbidimetric ultrasensitive assay (Tina-quant
CRP, Latex, Roche Diagnostics GmbH, Mannheim, Ger-
many) (Hitachi 902 Automatic Analyser, Tokyo, Japan).
The %CVof the CRP between run of assay was 5.8% at con-
centration for 5.5 mg/L and 1.5% in run with 4.0 mg/L.
Intact parathormone (iPTH, 1e84) and MID-osteocalcin
were analyzed by electrochemiluminescence immunoassay
(Elecsys Modular Analytics 2010 Roche, Hitachi, Tokyo,
Japan). Osteoprotegerin (OPG) and fetuin-A were deter-
mined by ELISA (MicroVue Eia Kit. Quidel Corp. Specialty
Products, San Diego, CA and Epitope Diagnostic Inc., San
Diego, CA, respectively). The intra-assay precision was
4.8e5.5% and inter-assay precision was 5.7e6.8%. Resid-
ual glomerular filtration rate (GFR) was measured as the
average of 24 h urine urea and creatinine clearance.
Echocardiographic Measurements
Heart valve calcification was defined as bright echoes
of O1 mm on one or more cusps of the aortic valve or
mitral valve or mitral annulus or both and were measured
using two-dimensional echocardiography using a digital
commercial harmonic imaging ultrasound system with
Table 1. Baseline clinical and biochemical characteristics of 124
patients on dialysis
Age (years) 46 (30e54)
Gender n (male %) 85 (68)
Diabetes n (%) 63 (51)
Smoking status n (%) 68 (55)
BMI (kg/m2) 25  4.43
Systolic BP (mmHg) 134  27
Diastolic BP (mmHg) 83.8  15.6
Time on PD (month) 1.4  1
Dialysis n (CAPD/APD) 53/58
GFR (ml/min/1.73 m2) 2.3 (1.18e5.7)
Glucose (mg/dL) 96 (87e130)
Urea (mg/dL) 126  41
sCrea (mg/dL) 9.1 (6.5e11.4)
TC (mg/dL) 186 (164e221)
Albumin (g/dL) 3.48 (3.1e3.8)
cCa (mg/dL) 8.9 (8.3e9.6)
PO4 (mg/dL) 4.6 (3.8e5.9)
iPTH (pg/mL) 104 (85e186)
Fetuin (ng/mL) 48  16
Osteocalcin (ng/mL) 176 (104e300)
hs-CRP (mg/L) 1.6 (0.46e4.8)
Phosphatase alkaline (IU/L) 92 (71e128)
Osteoprotegerin (pmol/L) 11.6 (7.5e15.5)
BMI, body mass index; PD, peritoneal dialysis; CAPD, continuous ambu-
latory peritoneal dialysis; APD, automated peritoneal dialysis; GFR,
glomerular filtration rate; BP, blood pressure; TC, total cholesterol; hs-
CRP, high-sensitivity C-reactive protein; iPTH, intact parathormone.
Continuous data are expressed as mean  SD; unless specified otherwise
median (interquartile range).
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Philips Medical Systems, Service Hardware Rev D.0, Bo-
thell, WA) with subjects lying in left decubitus position.
Echocardiography was performed according to the recom-
mendations of the American Society of Echocardiography
(15) by a single observer and images were analyzed by a
single experienced cardiologist who was blinded to all clin-
ical details. Sensitivity and specificity for echocardio-
graphic detection of calcium in the mitral valve and
aortic valve were reported to be 76% and 89e94%, respec-
tively (16).
Statistical Analysis
Data are expressed as mean  SD or median and interquar-
tile range, or frequencies according variable characteristics
and distributions. In non-normally distributed variables,
logarithmic transformations were applied. Changes be-
tween the final and initial evaluations are indicated as delta
(D). Differences between groups were analyzed by Student
t-test or Mann-Whitney U test for independent samples, ac-
cording to variable characteristics and distributions. c2 tests
were used for differences in proportion. To analyze differ-
ences between basal and final evaluations, paired-samples
t test was used. Rho Spearman and Pearson’s correlation
coefficient was used to test associations between two types
of parameters. Uni- and multivariate logistic regression was
used to identify risk factors for the development of MVC or
AVC; p #0.05 was considered to be significant in all ana-
lyses. SPSS Windows v.15 was used for all statistical
analyses.Results
A total of 124 patients from the total incident dialysis pop-
ulation were included in the final analysis.
Baseline Characteristics
Demographic, clinical and biochemical baseline character-
istics of the 124 patients are shown in Table 1. Time on
dialysis at baseline evaluation was 1.4  1.0 months. No
patient had evidence of valve calcification in the initial
echocardiographic evaluation. Male gender was over-
represented with 68% of the cases, half of the patients were
diabetic, 16 (12.9%) had urinary volume!100 mL/day and
the proportions in CAPD and APD were similar. Assign-
ment to a dialysis modality was according to patient prefer-
ence with orientation by the healthcare team and without
the intervention of the researchers.
Follow-up
All 124 patients completed the follow-up period, and the
final evaluation was done 12.35  1.02 months after thebaseline evaluation. At the end of the follow-up period,
valve calcifications were detected in 57 (46%) patients.
The aortic valve was calcified in 33 cases (57.8%), the
mitral valve in 15 cases (26.3%) and in nine cases
(15.8%) both valves were calcified. There was no correla-
tion in the presence or magnitude of calcifications between
valves; therefore, for the purposes of analysis, they were
considered independently: MVC (42 cases) and AVC (24
cases). Table 2 and Table 3 show the baseline and final
values for clinical and biochemical values of patients who
developed new MVC or AVC, and they were compared
with the 67 patients who did not develop valve calcifica-
tions (non-VC).
In the baseline evaluation, patients who developed MVC
were older, a greater proportion had diabetes, and they had
higher values of OPG when compared with patients who
did not develop calcifications. After 1 year, this group
showed increased values of values of hs-CRP, iPTH and
OPG when compared with the patients who did not develop
calcifications. In this group, we also observed significant in-
crements in creatinine, albumin, and phosphorus and de-
creases in GFR between baseline and final values. All
other characteristics were similar between baseline and
final evaluations and in groups.
At baseline, patients who developed AVC had higher
values of cholesterol than patients who did not develop
calcifications. No differences were found in the other
Table 2. Clinical characteristics of all patients with and without new development of mitral and aortic valve calcification at baseline and 1 year later
Variable
Non-valve calcification (n 5 67) Mitral valve calcification (n 5 24) Aortic valve calcificacion (n 5 42)
Baseline 1 year Baseline 1 year Baseline 1 year
Age 42  13 43  13 9  10a* 50  11b* 39  13 40  13
Gender m/f 47/20 47/20 8/7 9/15 23/10 23/10
DM y/n 31/36 31/36 18/6a* 18/6b* 14/19 14/19
Smokers (y/n) 39/28 39/28 16/8 16/8 15/18 15/18
BMI 25.2  4.5 25.9  4.1c* 27.1  1.4 27.5  2.6c* 24.9  4.4 26.8  5c*
SBP (mmHg) 135  26 141  27 139  26 144  26 128  26 143  29c*
DBP (mmHg) 85  14 89  13 85  14 89  10 83  17 89  17c*
GFR (ml/min/1.73 m2) 4.8  4 2.9  2c* 4.1  2.7 1.7  1.6c** 4.2  2 2.6  3
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; GFR, glomerular filtration rate.
Statistical analysis was done with valves.
aSignificant difference between mitral VC and non-mitral VC at baseline.
bSignificant difference between mitral VC and non-mitral VC after 1 year.
cDifferences between the baseline and final evaluations.
*Significant difference, p !0.01.
**Significant difference, p !0.05.
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After 1 year, the AVC group had incremental values of
iPTH, which were higher when compared with the patients
who did not develop calcifications, and significant incre-
ments were observed in BMI, SBP, DBP, creatinine, albu-
min, cCa, triglycerides and hs-CRP and decreases were
observed in cholesterol, fetuin and osteocalcin between
baseline and final evaluations. All other characteristics were
similar between baseline and final evaluations and groups.
Logistic regression was performed to analyze risk fac-
tors for developing CV. In the case of MVC, in univariateTable 3. Biochemical characteristics of all patients with and without developme
Variable
Non-valve calcification (n 5 67) Mitral val
Baseline 1 year Baseline
Glucose (mg/dL) 113  44 117  70 135  107
Urea (mg/dL) 122  43 119  3 132  31
sCrea (mg/dL) 9  3.5 11.4  4.5c* 8.4  2.4
Alb (g/dL) 3.4  0.5 3.8  0.4c* 3.3  0.5
cCa (mg/dL) 8.9  1.5 9.2  0.6 8.6  0.9
iPTH (pg/mL) 96 (48e179) 34 (9e144)c* 107 (71e13
PO4 (mg/dL) 4.6 (3.7e5.9) 4.8 (3.8e6.2) 5 (3.8e5.8
TC (mg/dL) 187  45 189  48 199  11
TG (mg/dL) 189  144 194  101 170  57
Fetuin-A (ng/mL) 48  16 39  16c* 52  17
OT (ng/mL) 172  99 138  98c* 189  89
hs-CRP(mg/L) 2 (0.6e4.9) 2.3 (0.8e6.3) 1.1 (0.6e2.
ALP (IU/L) 97  44 117  97 125  68
OPG (pmol/L) 12  6 12  6 15  7a**
cCa, albumin corrected calcium; TC, total cholesterol; TG, triglycerides; iPTH,
protein; ALP, alkaline phosphatase; OPG, osteoprotegerin.
Statistical analysis was done with valves.
aSignificant difference between mitral VC and non-mitral VC at baseline.
bSignificant difference between mitral VC and non-mitral VC after 1 year.
cDifferences between the baseline and final evaluations.
*Significant differences, p !0.01.
**Significant differences, p !0.05.analysis, age, diabetes, baseline and final concentrations
of OPG and iPTH (log), the incremented trend between
initial and final values of hs-CRP (Dhs-CRP), and iPTH
(DiPTH) were risk factors. Nevertheless, in multivariate
analysis (Model I), only iPTH was a risk factor for MVC.
Regarding changes of biochemical variables, Model II
showed that DiPTH remained an independent risk factor
as was also the case in AVC (RR 5 2.002, p !0.034
95% CI 1.052e3.81). Results are shown in Table 4.
To determine the association between the magnitude of
valve calcification (total mm2 of both valves) and the changesnt of mitral and aortic valve calcification at baseline and 1 year later
ve calcification (n 5 24) Aortic valve calcification (n 5 42)
1 year Baseline 1 year
129  61 119  65 119  63
138  3b** 130  42 115  36
12.2  3c* 9  3 11.6  3.5c*
3.6  0.5c* 3.5  0.5 3.7  0.4c*
9  0.8 8.6  0.8 9.0  0.7c*
3) 208 (79e296)b* 106 (64e195) 153 (22e305)b*
) 5.2 (4.8e6.8)c* 4.6 ( 3.8e6) 5.1 (4.6e6.1)c**
181  9 202  43a* 187  41c*
201  101 186  92 214  111c*
41  16 49  16 45  16c**
178  107 202  92 180  101c*
6) 4.4 (1.5e8.7)bc* 1.1 (0.6e4.6) 2.9 (0.8e7.4)c*
108  58 110  60 103  47
17  7bc* 13.1  6 14.6  7c*
intact parathormone; OT, osteocalcin; hs-CRP, high-sensitivity C-reactive
Table 4. Risk factors for mitral valve calcification
Univariate Multivariate
RR p 95% CI
Model I Model II
RR p 95% CI RR p 95% CI
Age (years) 1.051 0.02 1.06e1.09 1.044 0.27 0.96e1.12 1.05 0.22 0.97e1.13
DM (yes) 0.287 0.01 0.10e0.8 0.618 0.66 0.07e5.38 0.81 0.83 0.12e5.42
OPG 1.15 0.008 1.03e1.21 1.032 0.73 0.86e1.23 - - -
PTH (log) 7.41 0.04 1.08e50.5 8.93 0.03 1.12e71.71 - - -
DCRP (mg/L) 1.09 0.04 1.04e1.19 - - - 0.92 0.49 0.73e1.16
DPTH (log) 3.45 0.021 1.20e9.96 - - - 4.6 0.03 1.14e18.4
DOPG 1.08 0.17 0.96e1.2 - - - 1.10 0.21 0.94e1.28
DM, diabetes mellitus; OPG, osteoprotegerin; CRP, C-reactive protein; PTH, parathormone.
Logistic regression.
Significant difference, p !0.05.
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with VC were with DCRP (r 5 0.20, p !0.03), DOPG
(r 5 0.23, p !0.01) and DiPTH(r 5 0.22, p !0.05)
throughout the study. The correlation between DOPG and
DhsCRP was (r 5 0.25, p!0.009), DiPTH with Dserum al-
bumin (r 5 0.24, p !0.04), Dalbumin with Dhs-PCR
(r 5 e0.20, p !0.03) and Dhs-PCR with Dphosphorus
(r 5 0.22, p !0.02). There were no significant correlations
between valve calcification and gender, time on dialysis
and the other biochemical factor of osteoblastic activity.
An additional analysis was performed to study factors
related with faster development of valve calcifications. Pa-
tients were divided into two categories: slow calcificationsTable 5. Clinical and biochemical characteristics of 124 patients on dialysis wit
Slow development of valvular calcification
Patients n (%) 103 (83%)
Age (years) 42  13
Gender n (m/f) 71/34
DM (n) 49/56
BMI (kg/m2) 24  4
Smokers (n) 57/48
Systolic BP (mmHg) 130 (113e150)
Diastolic BP (mmHg) 84 (73e95)
Glucose (mg/dL) 96.2 (87e130.1)
Urea (mg/dL) 124.1  41.9
sCreatinine (mg/dL) 9.16  3.4
GFR (ml/min/1.73 m2 ) 3.9 3.8
Alb (g/dL) 3.7 0.3
cCa (mg/dL) 8.5 (8e9.1)
iPTH (pg/mL) 99 (56e187)
PO4 (mg/dL) 4.9  1.5
TC (mg/dL) 184.7 (164e225)
Fetuin (ng/mL) 49.01  16.61
OT (ng/mL) 175 (94e300)
hs-CRP (mg/L) 1.9 (0.5e5)
ALP (IU/L) 92 (71e127)
OPG (pmol/L) 9.9 (7.2e15.9)
DM, diabetes mellitus; cCa, albumin corrected calcium; TC, total cholesterol; iP
tive protein; ALP, alkaline phosphatase; OPG, osteoprotegerin.
Continuous data are expressed as mean  SD unless otherwise specified.
Median (interquartile range).in any valve (n 5 103) and fast calcifications in any valve
(n 5 21). The cutoff point was 30 mm2 in total.
Patients with fast progression of VC were older, had
DM, and had high levels of OPG and low levels of albumin
and GFR (Table 5).Discussion
Data herein reported show a frequent and rapid de novo
development calcification of mitral and aortic valves in
patients starting treatment with PD. Data also show lack
of correlation between mitral and aortic valve calcifica-
tion as well as different risk factors for calcification inh slow and rapid development of valve calcification
Rapid development of valvular calcification p
21 (17%)
48  11 0.02
14/7 NS
16/5 0.012
26  4 NS
12/9 NS
133 (117e152) NS
79 (74e90) NS
103.3 (88.2e138.2) NS
132.8  38.3 NS
8.73  2.10 NS
2.5 1.4 0.04
3.4 0.3 0.04
8.5 (7.7e9.4) NS
106 (71e194) NS
5  1.5 NS
197.7 (169e234.4) NS
49.39 (38.41e64.86) NS
138.3 (106.4e300) NS
1.2 (0.6e3.8) NS
94 (82e139) NS
16.8 (11.8e22.4) 0.009
TH, intact parathormone; OT, osteocalcin; hs-CRP, high-sensitivity C-reac-
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different mechanisms underlying the damage in different
valves.
A significantnumber ofpatients developednewvalve calci-
fication in the relatively short period of 1 year of follow-up:
26.3% in the mitral valve and 57.8% in the aortic valve. These
are not unexpected rates of damage because similar or even
higher rates of calcification have been reported in several
studies in prevalent HD and PD patients (4e6).
In spite of general similarities of this study with other
previous studies, it is necessary to underline differences.
Most previous reports were oriented to the analysis of con-
sequences or impact of valve calcification on clinical out-
comes such as morbidity and mortality of cardiovascular
origin (17,18). However, regarding valve calcification pro-
cess, they are cross-sectional analyses on prevalent HD or
PD populations where an adequate analysis of risk factors
for valve calcification was lacking; this is particularly
important for biochemical data because it was obtained
late, just at the time of valve calcification detection (19).
We did not find correlation of presence or magnitude of
calcifications between mitral and aortic valves, which sug-
gests different mechanism and risk factors for its
development.
The aortic valve was more frequently affected than the
mitral valve, which has been previously noted (5,20), but
no special considerations were made in those reports.
On the other hand, in the mitral valve, calcification is
associated with certain traditional risk factors and biochem-
ical changes, as discussed below.
As expected, traditional cardiovascular risk factors such
as age and diabetes were found to be risk factors for MVC
in the univariate logistic regression analysis. Inflammation
represented by increased levels of hs-CRP was also signif-
icant. Patients who developed MVC had an incremental
trend of hs-CRP serum concentration from initial to final
stage, emphasizing the role of inflammation in the calcifica-
tion process. This is in line with what has previously been
reported (21,22). Mineral metabolism-related variables
were also important; serum phosphorus increased between
the first and last evaluation. In most of the patients studied,
iPTH was !150 pg/mL, the suggested minimal value in
clinical practice guidelines (150e300 pg/mL) (23).
Although patients with MVC were not outside the range
(median: 208 pg/mL), they differed with non-VC, showing
higher values of iPTH and a trend to increase iPTH
levels from baseline to final evaluation. Previous studies
mentioned the role of mineral environment in calcification
process where hyperphosphatemia seems to be particularly
important (24,25). Our data are congruent with that concept
(median: 5.2 mg/dL). Whether iPTH has a role in calcifica-
tion is a matter of discussion. In this study, iPTH remained
essentially low, and the small increment observed may be
secondary to increment in serum phosphorus concentration
more than a direct effect on calcification.OPG levels at baseline and final evaluation were signif-
icant risk factors for MVC. The same picture has been
found in vascular calcification (26). Experimental studies
have demonstrated the OPG inhibitory effect on calcifica-
tion (27,28); therefore, high OPG levels as a risk factor
for MVC may sound contradictory. However, in the clinical
context (29), OPG levels should be interpreted as a conse-
quence of active calcification because it is synthesized and
secreted by cells with osteoblast activity. The amount
secreted may not only be derived from valves being calci-
fied, but also from arteries being calcified. Correlation be-
tween MVC and arterial calcification has been previously
reported (30e32). Data suggest that the inflammatory state
may induce overexpression of OPG as has been previously
demonstrated in experimental studies (33) and that valvular
endothelial cells unleash the pathway for osteogenic differ-
entiation and calcification of the same. This is supported by
the observation that a correlation is found between DOPG
and Dhs-CRP (r 5 0.25, p !0.009).
In the multivariate logistic regression, only PTH and
DPTH remained as independent risk factors, probably due
to the strong correlation between variables, as was the case
with DiPTH with Dserum albumin, (inverse) Dalbumin and
Dhs-PCR and Dhs-PCR with Dserum phosphorus.
Calcification of the aortic valve is associated with cyclic
mechanical stress derived from hemodynamic overwork as
well as biochemical alterations.
Regarding development of AVC, patients in this group
had only small but significantly higher values of serum
cholesterol than non-VC group as in another study of
non-renal patients (34) and showed significant increments
from baseline to final evaluation in BMI, SBP, DBP, sCr,
cCa, triglycerides and hs-CRP and decreases were observed
in fetuin. In spite of these differences, only PTH was an in-
dependent risk factor for AVC, similar to another study for
AVC (10).
Patients with rapid progression (O30 mm2) during 1 year
of VC were older, had DM and had high levels of OPG and
low levels of albumin and GFR, as reported in others studies
(19,35,36). It is interesting to note that elevated concentra-
tions of OPG persist in our patients with VC.
Our study has some limitations. It has a small sample
derived from stringent selection criteria, as the decision
was to include only patients free of detectable valve calci-
fication. However, it should be noted that restrictions al-
lowed us to clarify the beginning of the calcification
process. Another limitation refers to the relatively short
follow-up time. We should mention that other studies report
periods of 16 months, very similar to this study (13).
In summary, heart valve calcification is a frequent and
rapid phenomenon that seems to affect mitral and aortic
valves in different ways and to different magnitudes. Age,
diabetes, osteoprotegerin, parathormone and C-reactive
protein are risk factors for mitral calcification and iPTH
for aortic valve in incident dialysis patients.
644 Avila-Dıaz et al./ Archives of Medical Research 44 (2013) 638e644The results offer a new perspective on knowledge about
the pathophysiology of VC in patients on dialysis that may
orient towards new prevention and treatment strategies for
the cardiovascular complications of chronic kidney disease.Acknowledgments
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